You searched for "correction"
The management of possibly progressive pterygium
A 43-year-old Sudanese male patient is referred by his GP with a fleshy lesion encroaching the nasal cornea for the last six months. History Make note of: risk factors, i.e. UV exposure and ocular irritation - history of living in...The eye as a window to the brain: Non-invasive neuromonitoring
This article has been verified for CPD. Click the button below to answer a few short questions and download a form to be included in your CPD folder. Neuromonitoring, for example in conditions causing raised intracranial pressure (ICP) such as...
The Sclera and Systemic Disorders (3rd Edition)
An interesting historical introduction captures the reader’s attention as the journey begins into exploring the peculiarities and pathologies of ‘dura tunica of Vesalius’, a term coined by anatomists of the middle ages. This refers to what we today identify as...
A case study of posterior globe flattening in idiopathic intracranial hypertension
The authors present a single case of posterior globe flattening without papilloedema in idiopathic intracranial hypertension. The case was a 64-year-old woman with a one-year history of transient visual loss in her left eye only. Visual acuity was 20/20 in...
Possible mechanism for infant development of secondary glaucoma
The authors consider published evidence with regard to potential causative mechanisms for secondary glaucoma that follows infant lensectomy. They review clinical and laboratory studies. The mechanism they propose is that the original lensectomy surgery releases immature anterior lens cells into...MicroPulse Transscleral Laser Therapy: A Prospective UK Study
Register now to participate. Eagerly anticipated and now underway – a landmark UK medical research study on MicroPulse® Transscleral Laser Therapy (MPTLT) for the treatment of glaucoma using Iridex’ Cyclo G6® Laser and the MicroPulse P3® Delivery Device. A NICE-compliant...
The effects of anti-VEGF therapy for NvAMD on retinal vasculature
This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...Jessica Bartlett joins Glaukos as Territory Manager, North West England / Yorkshire
Glaukos Corporation is delighted to announce the appointment of Jessica Bartlett to the position of Territory Manager, Northwest, and Yorkshire.Simon Lysaght joins Glaukos as Territory Manager, Ireland
Glaukos Corporation is delighted to announce the appointment of Simon Lysaght to the position of Territory Manager, Ireland.Raphaél Ervinckx joins Glaukos
Glaukos Corporation has appointed Raphaél Ervinckx as Vice President and General Manager for the EMEAI region, marking a strategic move to support the company’s continued international growth. Raphaël Ervinckx brings extensive experience in the ophthalmology sector, most recently serving as...
Intravitreal bevacizumab vs. ranibizumab in the treatment of macular oedema due to BRVO
This is a randomised, prospective, non-inferiority trial of 75 patients with macular oedema due to a branch retinal vein occlusion (BRVO) who received intravitreal injections of ranibizumab or bevacizumab after 1:1 block randomisation. This study is to measure the difference...
